155
Participants
Start Date
June 20, 2017
Primary Completion Date
May 29, 2019
Study Completion Date
September 21, 2020
Atezolizumab
Atezolizumab, 840 mg intravenously every two weeks (Q2W) on Days 1 and 15 of each 28-day cycle, until loss of clinical benefit
Cobimetinib
Cobimetinib, 60 mg orally once daily (QD) on Days 1-21 of each 28-day cycle, until loss of clinical benefit
Atezolizumab
Atezolizumab, 840 mg intravenously on Day 15 of Cycle 1; thereafter Q2W on Days 1 and 15 of Cycle 2 and all subsequent 28-day cycles, until loss of clinical benefit
Atezolizumab
Atezolizumab, 1200 mg intravenously every three weeks (Q3W) on Day 1 of each 21-day cycle, until loss of clinical benefit
Johese Clinical Research, Centurion
Melanoma Institute Australia, North Sydney
Blacktown Hospital, Blacktown
Wits Clinical Research; Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg
Mid North Coast Cancer Institute, Port Macquarie
Peter Maccallum Cancer Centre, Melbourne
Alfred Hospital, Melbourne
Greenslopes Private Hospital; Clinic Pharmacy, Greenslopes
Flinders Medical Centre, Bedford Park
Cancercare, Port Elizabeth
Cancercare, George
Cape Town Oncology Trials, Cape Town
GVI Constantiaberg, Cape Town
Hospital Clinico Universitario de Santiago, Santiago de Compostela
MD Anderson Cancer Center, Madrid
Hospital Universitario Ramón y Cajal; Pharmacy, Madrid
Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid
Hospital Universitario La Paz; Servicio de Oncologia, Madrid
Clínica Universidad de Navarra, Pamplona
National Cancer Institute MOH of Ukraine, Kiev
Sarah Cannon Research Institute, Nashville
Sumy Regional Clinical Onc Ctr, Sumy
Hospital Universitario Virgen Macarena, Seville
Karmanos Cancer Institute, Detroit
Public Institution: City Multispecialty Clinical Hospital #4 under Dnipropetrovsk Regional Council, Dnipropetrovsk
Washington University School of Medicine, St Louis
Baylor University Medical Center, Dallas
University Clinical Centre of the Republic of Srpska, Banja Luka
Lviv State Oncology Regional Treatment and Diagnostic Centre, Lviv
University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora
HonorHealth Research Institute - Bisgrove, Scottsdale
Central Municipal Hospital - Uzhgorod State University, Uzhhorod
University Clinic Ctr Sarajevo, Sarajevo
Instituto de Ensino e Pesquisa Clinica do Ceara, Fortaleza
Cenantron - Centro Avancado de Tratamento Oncologico, Belo Horizonte
Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro
Hospital Sao Vicente de Paulo, Passo Fundo
Hospital das Clinicas - UFRGS, Porto Alegre
Hospital Sao Lucas - PUCRS, Porto Alegre
Hospital Amaral Carvalho, Jaú
Steve Biko Academic Hospital; Oncology, Pretoria
Hospital Universitari Quiron Dexeus, Barcelona
Hospital Clinic I Provincial, Barcelona
Hoffmann-La Roche
INDUSTRY